查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1978740

冠狀動脈繞道手術手術市場：依移植類型、手術類型、應用、最終用戶分類，全球預測，2026-2032年

Coronary Artery Bypass Grafts Market by Graft Type, Procedure Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，冠狀動脈繞道手術手術市場價值將達到 208.9 億美元，到 2026 年將成長至 219.6 億美元，到 2032 年將達到 298.8 億美元，複合年成長率為 5.24%。

主要市場統計數據
基準年 2025 208.9億美元
預計年份：2026年 219.6億美元
預測年份 2032 298.8億美元
複合年成長率 (%) 5.24%

對目前冠狀動脈繞道手術手術的現狀進行全面概述，重點介紹臨床進展、技術進步以及對醫療保健提供者的營運影響。

本執行摘要首先簡要概述了現代冠狀動脈繞道手術移植術（CABG）的生態系統，重點闡述了正在重塑醫療服務模式的技術、臨床和運營因素。過去十年，影像學、血管獲取和手術全期管理技術的進步改變了臨床路徑，而手術方式的多樣化也帶來了新的技能要求、資金規劃考量和患者選擇模式。

快速的臨床創新、手術多樣化和供應鏈合作正在重塑冠狀動脈再灌注途徑和醫療保健重點。

由於技術創新、器械小型化和多學科診療模式的推動，冠狀動脈繞道手術移植術領域正在經歷變革。新興技術正在縮小傳統開胸手術與微創手術之間的差距，促使許多醫療機構重新評估臨床路徑，並將加速病患復健和減少住院資源作為優先事項。

本研究評估了 2025 年美國關稅變化對移植材料供應、設備採購和供應鏈韌性的累積營運和採購影響。

2025年政策和貿易趨勢帶來的關稅變化對冠狀動脈繞道手術移植術相關技術的整個採購、製造和分銷管道產生了連鎖反應。這些政策措施顯著影響了移植準備和供應系統中使用的進口器材、專用設備和組件的成本結構，迫使許多供應鏈相關人員重新評估其採購和庫存策略。

有針對性的細分分析揭示了移植類型、手術技術、醫療環境和臨床應用如何影響不同的臨床和操作決策過程。

基於細分市場的分析揭示了每種移植類型、手術技術、最終用戶環境和應用領域對臨床和採購的不同影響。每種情況都存在獨特的操作和實施方面的考量。在比較不同類型的移植時，如果長期通暢性是首要考慮因素，動脈移植往往是手術中的首選。另一方面，在某些解剖和臨床情況下，靜脈移植仍然佔據主導地位，這會影響庫存組成和外科醫生培訓的重點。

影響招募模式、籌資策略和臨床專案設計的區域趨勢（包括美洲、歐洲、中東、非洲和亞太地區）。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的各種手術組合、技術應用和供應鏈策略有顯著影響。在美洲，三級醫療機構和綜合醫療保健系統高度重視技術的推廣，這些機構和系統能夠支援資本密集技術和系統化的培訓計畫。這種環境有利於機器人手術和混合手術方式的快速試點，同時也要求提供關於其臨床和營運效益的嚴格證據。

重新定義產品差異化和臨床夥伴關係：設備、機器人和服務供應商之間的競爭格局和策略行動

冠狀動脈繞道手術手術 (CABG) 領域的競爭格局反映了成熟手術器械製造商、新興機器人和影像公司以及提供全面支援的服務型供應商之間的互動。主要企業持續投資於血管採集器械、吻合裝置和耗材的迭代改進，旨在簡化工作流程並降低治療結果的差異性。同時，機器人和內視鏡系統正在革新傳統的手術室配置，促進技術提供者和臨床中心之間開展共同開發和培訓計畫的合作協議。

臨床和商業領導者需要採取切實可行的策略行動，以協調技術採用、採購彈性和人才發展，從而實現專案的永續成長。

產業領導者應優先考慮分階段、循證的技術採納方法，使臨床目標、營運能力和財務管理保持一致。首先，應進行多學科評估，包括手術量、外科醫生培訓需求和手術全期流程，以確定各機構在哪些領域投資微創手術和機器人技術能夠帶來最大的臨床和營運回報。儘早與臨床促進者、護理領導者和供應鏈合作夥伴開展合作，將有助於製定切實可行的採納計劃，並為認證規劃提供支援。

我們透過實證調查方法確保提供可操作的見解，這些方法結合了與臨床醫生的直接訪談、監管分析、文獻綜述和案例研究。

本執行摘要的研究基於多方面方法，旨在整合臨床證據、營運經驗和市場訊息，同時保持分析的嚴謹性。主要研究包括對心臟外科醫生、循環系統專科護理師、相關醫療保健專業人員、採購經理和醫院管理人員進行結構化訪談，以直接了解手術選擇、培訓限制和供應鏈優先事項。這些定性研究結果與同行評審的臨床文獻、指南文件以及記錄手術結果和比較技術評估的註冊資料進行了交叉比對。

簡潔的整合，強調冠狀動脈再灌注的實際進展，優先考慮技術可行性、操作可行性和供應鏈穩定性之間的平衡。

總之，冠狀動脈繞道手術手術的發展並非處於完全替代階段，而是處於實踐演進階段。微創技術、機器人技術和手術全期通訊協定的進步正在拓展治療選擇，並為改善患者體驗創造機會，但諸如培訓要求、資金限制和供應鏈考量等組織現實因素正在減緩變革的步伐。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：冠狀動脈繞道手術手術市場：依移植類型分類

  • 動脈
  • 靜脈

第9章：冠狀動脈繞道手術手術市場：依手術類型分類

  • 常規泵浦上
  • 微創手術
    • 內視鏡
    • 機器人
  • 非泵送

第10章：冠狀動脈繞道手術手術市場：依應用領域分類

  • 多血管疾病
  • 單血管疾病

第11章：冠狀動脈繞道手術手術市場：依最終用戶分類

  • 門診手術中心
  • 心臟中心
  • 醫院

第12章：冠狀動脈繞道手術手術市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：冠狀動脈繞道手術手術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章冠狀動脈繞道手術手術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國：冠狀動脈繞道手術手術市場

第16章 中國：冠狀動脈繞道手術手術市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AtriCure, Inc.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • ConMed Corporation
  • CryoLife, Inc.
  • Edwards Lifesciences Corporation
  • enVVeno Medical Corporation
  • Getinge AB
  • LivaNova PLC
  • Medtronic plc
  • Teleflex Incorporated
  • Terumo Corporation
  • Transonic Systems Inc.
  • Vascular Graft Solutions Ltd.
Product Code: MRR-2A0283E2559F

The Coronary Artery Bypass Grafts Market was valued at USD 20.89 billion in 2025 and is projected to grow to USD 21.96 billion in 2026, with a CAGR of 5.24%, reaching USD 29.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.89 billion
Estimated Year [2026] USD 21.96 billion
Forecast Year [2032] USD 29.88 billion
CAGR (%) 5.24%

A comprehensive orientation to the current coronary artery bypass graft environment highlighting clinical evolution, technology adoption, and operational implications for providers

This executive summary opens with a concise orientation to the contemporary coronary artery bypass graft ecosystem, framing the technological, clinical, and operational forces that are reshaping care delivery. Over the past decade, advances in imaging, conduit harvesting techniques, and perioperative management have altered clinical pathways, while procedural diversification has introduced new skill requirements, capital planning considerations, and patient selection paradigms.

Clinical teams are increasingly balancing traditional open techniques with less invasive approaches that aim to reduce recovery time and resource utilization. At the same time, hospitals and specialized centers are reassessing program structures to accommodate robotics, endoscopic instrumentation, and dedicated hybrid operating rooms. These shifts have implications for staffing models, training curricula, and capital allocation decisions across institutions.

Moreover, the patient population undergoing bypass procedures is evolving, with demographic trends and comorbidity profiles influencing graft selection and perioperative strategies. As a result, stakeholders must integrate clinical evidence, technology capability, and operational feasibility to design durable care pathways. The introduction prepares the reader to explore subsequent sections that examine landscape transformations, policy impacts, segmentation intelligence, regional dynamics, competitive positioning, and pragmatic recommendations for leaders aiming to refine their approach to coronary artery bypass graft care.

How rapid clinical innovations, procedural diversification, and supply chain partnerships are reshaping coronary revascularization pathways and institutional priorities

The coronary artery bypass graft landscape is undergoing transformative shifts driven by innovations in technique, device miniaturization, and multidisciplinary care models. Emerging technologies have narrowed the gap between traditional open surgery and less invasive strategies, prompting many centers to reevaluate clinical pathways to prioritize faster recoveries and reduced inpatient resource use.

Concurrently, procedural diversification is influencing workforce development and privileging policies. As minimally invasive endoscopic and robotic-assisted techniques gain traction alongside off-pump and conventional on-pump approaches, institutions face the dual challenge of ensuring procedural volume to maintain proficiency while investing in simulation and proctoring programs. This dynamic fosters collaborative relationships between cardiac surgeons, interventional cardiologists, anesthesiologists, and perioperative teams to optimize patient outcomes.

Supply chain innovation and vendor partnerships are also affecting adoption curves. Manufacturers are offering integrated systems and service models that lower the barrier to entry for smaller programs, while reimbursement environments and hospital resource constraints shape rollout timelines. In parallel, patient-centered care expectations-driven by shorter hospital stays and quicker return-to-function-are motivating providers to adopt evidence-informed protocols that support accelerated recovery without compromising long-term graft patency. Taken together, these shifts are redefining how institutions deliver coronary revascularization across the care continuum.

Assessing the cumulative operational and procurement consequences of United States tariff shifts in 2025 on graft supplies, device sourcing, and supply chain resilience

Policy and trade dynamics in 2025 introduced tariff changes that ripple across procurement, manufacturing, and distribution channels linked to coronary artery bypass graft technologies. These policy measures have had a pronounced effect on cost structures for imported instruments, specialized devices, and component materials used in graft preparation and delivery systems, prompting many supply chain stakeholders to reassess sourcing and inventory strategies.

As a consequence, procurement teams are increasingly emphasizing supplier diversification and regional manufacturing partnerships to mitigate exposure to cross-border policy volatility. Clinical leaders have responded by working with supply chain counterparts to identify clinically equivalent alternatives and to validate device interoperability to maintain procedural continuity. In parallel, contract negotiations with vendors have grown more intricate, with greater focus on total-cost-of-ownership clauses, service level agreements, and contingencies for customs-related delays.

Operationally, some institutions have accelerated investments in reusable instrumentation where clinically appropriate and enhanced sterilization capacity to offset lead-time risks. Regulatory compliance and quality assurance teams have also become more central to vendor selection, ensuring that alternative sources meet clinical performance expectations. Ultimately, the combined effect of trade policy shifts has underscored the importance of resilient procurement strategies and closer alignment between clinical, supply chain, and commercial stakeholders.

Targeted segmentation insights showing how graft type, procedure modality, care setting, and clinical application drive distinct clinical and operational decisions

Segmentation-based insights reveal differentiated clinical and procurement implications across graft types, procedure modalities, end-user settings, and applications, each carrying distinct operational and adoption considerations. When examining graft type distinctions, arterial conduits often command procedural preference where long-term patency is prioritized, whereas venous grafts remain a mainstay for specific anatomic and clinical scenarios, influencing inventory mix and surgeon training priorities.

Procedure type distinctions further nuance adoption pathways: conventional on-pump approaches anchor many institutional programs due to broad practitioner familiarity and predictable workflows, while off-pump techniques are leveraged in select populations to reduce cardiopulmonary bypass-related sequelae. Minimally invasive strategies, including endoscopic harvesting and robotic-assisted operations, are expanding into centers that can support advanced instrumentation and dedicated perioperative teams, and they necessitate coordinated investments in training, simulation, and case scheduling.

End-user segmentation underscores divergent operational requirements across ambulatory surgical centers, cardiac centers, and hospitals. Ambulatory facilities emphasize throughput, rapid recovery protocols, and lean inventory models, whereas specialized cardiac centers focus on high-acuity service portfolios and technology-intensive procedures. Hospitals balance both acute care responsibilities and broader surgical case mixes, requiring flexible supply agreements and cross-departmental coordination. Application-driven insights, differentiating multi-vessel disease from single-vessel disease, inform clinical pathway design and graft selection strategies, as patients with complex coronary anatomy often demand multi-disciplinary planning and resource-intensive perioperative care. These segmentation perspectives collectively guide targeted program design and procurement decisions.

Regional dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific that influence adoption patterns, procurement strategies, and clinical program design

Regional dynamics exert a strong influence on procedural mix, technology adoption, and supply chain strategies across the Americas, Europe Middle East and Africa, and Asia-Pacific geographies. In the Americas, there is a pronounced emphasis on innovation diffusion within tertiary centers and integrated health systems that can underwrite capital-intensive technologies and structured training programs. This environment supports rapid piloting of robotics and hybrid approaches while demanding rigorous evidence of clinical and operational benefit.

Across Europe, the Middle East and Africa, regional heterogeneity leads to varied adoption profiles; established cardiac centers in high-income countries emphasize outcomes-driven implementation with strong regulatory oversight, whereas emerging markets prioritize scalable solutions that improve access to care. Consequently, vendor engagement strategies must be adapted to account for reimbursement frameworks, local clinical guidelines, and variable infrastructure capabilities.

The Asia-Pacific region displays a broad spectrum of adoption velocities, with several markets actively pursuing capacity expansion and modernization of cardiac surgical services. Strategic partnerships between manufacturers and regional distributors have been pivotal in expanding access to advanced instruments and training. Across all regions, differences in demographic trends, prevalence of coronary disease, and health system organization shape workforce planning, procedural selection, and capital investment decisions, requiring market-specific approaches to clinical integration and commercialization.

Competitive landscape and strategic behaviors among device, robotics, and service providers that are redefining product differentiation and clinical partnerships

Competitive dynamics in the coronary artery bypass graft ecosystem reflect an interplay between established surgical device manufacturers, emerging robotics and imaging companies, and service-oriented vendors offering integrated support. Leading device firms continue to invest in iterative improvements to conduit harvesting tools, anastomotic devices, and disposables that aim to simplify workflows and reduce variability in outcomes. At the same time, robotics and endoscopic systems are disrupting traditional operating room configurations, prompting collaborative agreements between tech providers and clinical centers for co-development and training programs.

Strategic differentiation increasingly rests on bundled solutions that combine hardware, consumables, data analytics, and educational services. Vendors that demonstrate a clear pathway to reduce operating time, improve patient recovery metrics, or lower complication rates secure stronger clinical advocacy and preference. Meanwhile, aftermarket service models, remote monitoring, and surgeon credentialing offerings have become competitive levers as hospitals seek predictable performance and reduced lifecycle costs.

Partnerships between device manufacturers and academic centers facilitate evidence generation and real-world validation, which in turn informs adoption and reimbursement conversations. Supply chain partnerships and regional manufacturing footprints are also shaping competitive positioning, particularly for stakeholders aiming to ensure continuity of supply and responsive service across diverse geographies.

Practical strategic actions for clinical and commercial leaders to align technology adoption, procurement resilience, and workforce development for sustainable program growth

Industry leaders should prioritize a phased, evidence-driven approach to technology adoption that aligns clinical objectives with operational capacity and financial stewardship. Begin by conducting multidisciplinary assessments of procedure volumes, surgeon training needs, and perioperative pathways to identify which minimally invasive or robotic investments will yield the greatest clinical and operational returns for a given institution. Early engagement with clinical champions, nursing leadership, and supply chain partners ensures realistic implementation timelines and supports credentialing plans.

Next, pursue supplier agreements that emphasize flexibility, training support, and outcome-linked service commitments to mitigate operational risk. Where tariff- or policy-related procurement exposures exist, diversify sourcing and consider regional manufacturing partnerships to improve lead-time reliability. Invest in simulation and proctoring programs to accelerate proficiency while protecting patient safety, and integrate robust data collection to track perioperative outcomes, resource use, and patient-reported recovery metrics.

Finally, foster collaborative relationships with payers and regulatory stakeholders to highlight value propositions rooted in improved recovery times, reduced complications, and optimized care pathways. By combining clinical rigor with pragmatic procurement and workforce planning, leaders can scale advanced coronary revascularization approaches in a manner that balances innovation with measurable improvements in patient care.

An evidence-driven research methodology combining primary clinician interviews, regulatory analysis, literature review, and operational case studies to ensure actionable insights

The research underpinning this executive summary draws on a multi-method approach designed to synthesize clinical evidence, operational experience, and market intelligence while preserving analytical rigor. Primary research involved structured interviews with cardiac surgeons, perfusionists, allied health professionals, procurement directors, and hospital administrators to capture firsthand perspectives on procedural selection, training constraints, and supply chain priorities. These qualitative insights were triangulated with peer-reviewed clinical literature, guideline documents, and registries that document procedural outcomes and comparative technique evaluations.

Secondary analysis incorporated regulatory filings and device approvals to understand product lifecycles and safety profiles, alongside public policy materials that contextualize procurement and trade dynamics. Additionally, site-level case studies explored implementation pathways for minimally invasive and robotic programs, highlighting resource allocation, staff competency development, and throughput impacts. Quality assurance measures included cross-validation of interview themes, methodological transparency regarding data sources, and peer review by clinical subject-matter experts to ensure that interpretations reflect current practice realities.

Together, these methods provide a structured, evidence-informed basis for the insights and recommendations offered in this summary, with an emphasis on operational applicability and clinical integrity.

A concise synthesis emphasizing pragmatic evolution in coronary revascularization balancing technological promise with operational feasibility and supply chain stability

In conclusion, the coronary artery bypass graft environment is in a period of pragmatic evolution rather than wholesale replacement. Advances in minimally invasive techniques, robotics, and perioperative protocols are expanding therapeutic options and creating opportunities for improved patient experiences, while institutional realities such as training requirements, capital constraints, and supply chain considerations temper the pace of change.

Policy shifts and tariff dynamics have highlighted the importance of procurement resilience and closer collaboration between clinical and supply chain leadership. Segmentation insights demonstrate that graft selection, procedural modality, and care setting each demand tailored strategies that accommodate local clinical expertise and infrastructure. Regionally, diverse adoption patterns underscore the value of context-specific approaches that align technology deployment with reimbursement, workforce capacity, and population health needs.

For organizations seeking to navigate this transition, the balanced path forward involves phased investment, rigorous outcome tracking, and strategic supplier partnerships that emphasize service, training, and supply continuity. By synthesizing clinical evidence with operational planning, providers and industry partners can improve patient outcomes while building programs that are sustainable and responsive to future innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coronary Artery Bypass Grafts Market, by Graft Type

  • 8.1. Arterial
  • 8.2. Venous

9. Coronary Artery Bypass Grafts Market, by Procedure Type

  • 9.1. Conventional On Pump
  • 9.2. Minimally Invasive
    • 9.2.1. Endoscopic
    • 9.2.2. Robotic
  • 9.3. Off Pump

10. Coronary Artery Bypass Grafts Market, by Application

  • 10.1. Multi Vessel Disease
  • 10.2. Single Vessel Disease

11. Coronary Artery Bypass Grafts Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Centers
  • 11.3. Hospitals

12. Coronary Artery Bypass Grafts Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Coronary Artery Bypass Grafts Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Coronary Artery Bypass Grafts Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Coronary Artery Bypass Grafts Market

16. China Coronary Artery Bypass Grafts Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AtriCure, Inc.
  • 17.6. B. Braun Melsungen AG
  • 17.7. Baxter International Inc.
  • 17.8. ConMed Corporation
  • 17.9. CryoLife, Inc.
  • 17.10. Edwards Lifesciences Corporation
  • 17.11. enVVeno Medical Corporation
  • 17.12. Getinge AB
  • 17.13. LivaNova PLC
  • 17.14. Medtronic plc
  • 17.15. Teleflex Incorporated
  • 17.16. Terumo Corporation
  • 17.17. Transonic Systems Inc.
  • 17.18. Vascular Graft Solutions Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ARTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ARTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ARTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY VENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY VENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY VENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY CONVENTIONAL ON PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY CONVENTIONAL ON PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY CONVENTIONAL ON PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ROBOTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ROBOTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ROBOTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY OFF PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY OFF PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MULTI VESSEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MULTI VESSEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MULTI VESSEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY SINGLE VESSEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY SINGLE VESSEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY SINGLE VESSEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GCC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. GCC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. GCC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 103. GCC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GCC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. G7 CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. G7 CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. G7 CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 121. G7 CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. G7 CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NATO CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NATO CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NATO CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 127. NATO CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NATO CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)